Venous plasma concentrations ofbupivacaine were determined in eight cholecystectomy patients following multiple interpleural bolus instillations of bupivacaine 20 ml O.S% with adrenaline (S mgll) administered at six-to eight-hour intervals. The mean steady-state peak plasma concentration was 2.3 mgll (range 1.2-3.1 mgll); however, in three of the eight patients peak plasma concentrations were greater than 3 mgll. The mean accumulation ratio was found to be 1.6 (range 0.99-2.49), with steady-state occurring within the first 24 hours of drug administration. Mean apparent systemic plasma clearance was 0.16±0. 07l!kglh with a mean terminal half-life of S.8±2.3 hours measured at steady-state, values which were not significantly different (P> O.OS) from those values obtained following single inter pleural bolus dose administration.
associated with central nervous system toxicity is generally thought to be above 4 mg/l;ll however, convulsions have been reported at plasma concentrations as low as 2.3 mg/1 12 and 3.0 mgllY To date detailed pharmacokinetic studies on interpleural bupivacaine have been limited. 4 ,14 This study is a continuation of a detailed pharmacokinetic analysis of interpleural bupivacaine administered to patients undergoing elective cholecystectomy. In an earlier report l4 we examined the disposition of bupivacaine following the interpleural administration of a single bolus dose, while this study was designed to examine the steadystate pharmacokinetics of the drug after multiple interpleural bolus doses. A major concern regarding repeated administration of local anaesthetics is the possibility of drug accumulation and therefore the potential for drug-related toxicity. 
Patients
With approval from the Queen Elizabeth 11 Jubilee Hospital Ethics Committee and written informed consent, eight adult patients (three males and five females) between the ages of22 and 57 years were studied following elective surgery for cholecystectomy (Table 1) . Patients with a known history of hypersensitivity to local anaesthetics and/or a history of pleurisy, chronic liver disease, or epilepsy were excluded from the study.
Interpleural technique
The site of insertion of the interpleural catheter was changed from that used in the previous study14 as a result of a serious toxicity reaction (to be discussed elsewhere). As a consequence of this complication both the site of catheter insertion and the method of injection of the bolus of bupivacaine were altered (see below).
In this study the patient was rolled onto the left side while still paralysed and ventilated. A 16-gauge Tuohy needle was inserted in the sixth intercostal space at the posterior angle of the rib. The appropriate epidural catheter was then inserted into the pleural cavity using a loss-of-resistance technique. No further complications have arisen using this orocedure.
Dosage of bupivacaine
A central venous line introduced peripherally via a vein at the antecubital fossa was inserted intraoperatively. A chest X-ray was performed in the recovery area to confirm the satisfactory position of the central venous line and exclude the creation of a pneumothorax. Upon regaining consciousness in the recovery room, patients were administered an initial bolus dose via the interpleural catheter of 20 ml 0.5% bupivacaine with adrenaline (5 mg/l). The 20 ml bolus dose was given as 2 X 10 ml increments (each administered over approximately 60 seconds and separated by a five-minute interval). Subsequent intermittent interpleural instillations of 20 ml 0.5% bupi vacaine with adrenaline administered in an identical fashion were carried out in a general surgical ward. Repeated injections, based on the duration of analgesia achieved, varied over intervals of approximately six to eight hours. In seven of the eight patients six additional doses were given overall, while one patient (Patient 5) received an additional eight doses.
Blood collection and analysis
After each interpleural bolus dose of bupivacaine, with the exception of the last dose, 5 ml venous blood samples were taken at 15, 20 and 30 minutes (in order to estimate each peak concentration) and at approximately 480 minutes ('trough' concentration). More detailed sampling was undertaken following the last dose (at steadystate), with venous blood collected at 2,5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 240, 360 and 480 minutes.
The samples were centrifuged and the plasma deep-frozen and stored before analysis. Bupivacaine in plasma was measured by high pressure liquid chromatography using the method of Wiegand and ChOU 15 with minor modifications. With this procedure thp. drug and its internal standard [1-pentyl-2-(2' ,6'xylylcarbamoyl)-piperidine] are extracted from alkalinised plasma by hexane, and after evaporation of the hexane phase the residue is redissolved in a water-methanol mixture. The mobile phase for chromatography is methanol: sodium phosphate buffer (60:40) at a flow rate of 1.5 ml/min, with ultraviolet detection at 254 nm. The sensitivity of this assay for bupivacaine was found to be 0.1 mg/l, with an intra-and inter-day assay coefficient of variation of approximately 8% at a plasma concentration of 0.4 mg/1.
Pharmacokinetic analysis
Non-compartmental methods were employed for the pharmacokinetic analysis of the plasma concentration-time data. 14, 16 Terminal phase half-life (tl;') and apparent venous plasma systemic clearance (Cl s ) were calculated for bupivacaine.
The achievement of steady-state was assessed by visual inspection of the individual patient bupivacaine plasma concentrationtime curves following each bolus dose, where steady-state occurred at a point in time when each maximum (averaged to obtain the mean peak plasma concentration) and trough plasma concentrations of bupivacaine remained essentially unchanged from dose to dose ( Figure 1) .
The ratio of the maximum plasma concentration at steady-state to the maximum plasma concentration following the first bolus dose in individual patients was measured as an index of drug accumulation.
Pharmacokinetic variables for bupivacaine obtained in this study were compared with those values noted in our earlier single interpleural bolus studyl4 using the unpaired Student's Hest.
RESULTS

Figure
shows the venous plasma bupivacaine concentration-time profile following multiple interpleural bolus doses of 0.5% bupivacaine with adrenaline over 52 hours (seven doses) postoperatively for Venous Plasma Cone (mg/I) Patient 8. The plot is characteristic of those for all eight cholecystectomy patients, even allowing for the observation that Patient 8 had the lowest body weight of the patient group.
The mean peak plasma concentration at steady-state was 2.3 mg/l (range 1.2-3.1 mg/l). For three of the eight patients the peak plasma bupivacaine concentration recorded was greater than 3 mg/l, and the highest individual plasma concentration measured was 3.4 mg/l. An average accumulation factor of 1.60 (range 0.99-2.49) was noted ( Table 2 ).
The calculated pharmacokinetic parameters for bupivacaine are summarised in Table 2 . The mean apparent systemic venous plasma clearance of bupivacaine was found to be 0.16 lIkg/1 (SD 0.07) with a mean half-life of 5.8 h (SD 2.3). The values for bupivacaine clearance and half-life were found not to be significantly different from those values previously petermined in our single interpleural bolus dose study.14 DISCUSSION The efficacy of interpleural bupivacaine in the management of pain following upper abdominal surgery has been well documented. I -8 ,1O However, its use by bolus administration requires multiple interpleural instillations in order to provide adequate analgesic coverage for a patient's postoperative stay in hospital.
The average accumulation ratio of 1.6 found for bupivacaine in this study following dosage intervals of the drug of between six to eight hours indicates minimal accumulation of the drug after multiple interpleural dosage. However, it should be noted that there was a degree of patient variability in this measured ratio which ranged from approximately 1 to 2.5. For three ofthe eight patients the steadystate maximum venous plasma concentration was greater than 3 mg/l, a level which has occasionally been associated with central nervous system toxicity. However, none of our patients showed any signs of drug-related adverse effects. Only in two previous studies have plasma concentrations ofbupivacaine been measured following multiple interpleural administration. 2 • 17 Scheinin and colleagues 17 found that the average venous plasma concentration of bupivacaine 24 hours postoperatively in twenty elective postthoracotomy patients was 1.06 mg/l (SD 0.55, range 0.1-1.59 mg/I) when multiple doses of 20 ml bupivacaine 0.5% with adrenaline were administered at four-hour intervals four times daily. However, in some patients high values ofbupivacaine concentrations (up to 1.2 mg/l) were found in the drainage fluid. The other study2 was conducted with various doses of interpleural bupivacaine in twenty-one cholecystectomy patients. Nine of these patients received 20 ml doses of 0.5% bupivacaine-adrenaline every six hours and venous plasma concentrations in two patients reached l.9 and 2.4 mg/I. No serious sideeffects were noted in either study.
Our measured average venous steady-state peak plasma concentration was 2.3 mg/l which was reached within a period of approximately 24 h postoperatively ( Figure  1) Whether such accumulation occurs with the use of prolonged interpleural infusions will be the subject of a separate investigation in our laboratory. The consistency in our measured pharmacokinetic parameters for bupivacaine reinforces the previously mentioned discrepancy between our data 14 and that reported by Seltzer and co-workers. 4 Our lower values for apparent venous systemic plasma clearance and longer half-life, calculated from data obtained using the same analytical technique, were attributed principally to prolonged absorption of the drug from the pleural cavity due to possible differences in catheter placement in the two studies. It was hoped that catheter placement in our steady-state study could be determined by chest X-ray of the patients following the last administered dose of the drug. In two patients (Patients 1 and 2) this was satisfactorily performed and the epidural catheter in each case was located posterior to the lung. However, this procedure was abandoned in subsequent patients for safety reasons since Patients 1 and 2 reacted adversely to the contrast agent. The question of catheter placement and prolonged absorption of bupivacaine from the pleural cavity therefore remains unanswered. However, it is likely that our technique of administering the 20 ml of bupivacaine 0.5% with adrenaline as 2 X 10 ml injections may have contributed to a broadening of the venous plasma concentration-time curves and an apparent lengthening of the half-life.
In summary repeated administration of 20 ml doses of 0.5% bupivacaine-adrenaline at six-to eight-hour intervals into the pleural cavity was found to be safe and effective, being free of central nervous system and cardiac side-effects in this study. However, a few of our reported bupivacaine plasma concentrations are similar to those previously found to be associated with potentially dangerous cardiac and central nervous system toxic effects of the drug. Our findings suggest that inter-patient variability in the steadystate maximum venous plasma concentration and accumulation ratio for the drug can occur and some degree of caution is therefore indicated in the use of interpleural bupivacaine by the surgeon or anaesthetist. Further research with this technique of regional anaesthesia is also necessary.
